Press Releases
[NewsWire] SML Meditree Accelerates Expansion in the Global Clinical Trial Sample Analysis Market
Global Clinical Trial Sample Analysis Expected to Account for More Than 30% of
SML Meditree’s Projected 2024 Revenue
Strategic Location and Dedicated Global Team Strengthen Global Competitiveness
SML Meditree, which has established its expertise in clinical trial sample analysis since launching Korea’s first Central Lab service in Asia, is expanding its presence in the global market. Having actively prepared to strengthen its global competitiveness through the recruitment of analytical experts and expansion into advanced analytical areas, SML Meditree expects global clinical trial sample analysis to account for more than 30% of its projected revenue in 2024. This is regarded as an important indicator of the company’s analytical capabilities and growing global presence.
SML Meditree’s Analysis Center in Yangjae-dong, Seocho-gu, Seoul
Dedicated LC-MS/MS Analysis Room within the Analysis Center
SML Meditree’s analysis center is centrally located in Seoul, within one hour of Korea’s five major university hospitals. This strategic location enables the company to provide optimal services for PBMC (Peripheral Blood Mononuclear Cell) isolation, where speed and stability are particularly critical, earning a high level of trust from global sponsors. Recognizing these strengths, the company has recently secured multiple new contracts and established itself as a preferred candidate for consideration among global clients.
Having built trust through a wide range of long-term partnerships over more than a decade, SML Meditree has demonstrated particular strengths in the analysis of anticancer drugs and treatments for rare diseases, successfully meeting the demanding requirements of global sponsors in markets such as the United States and Japan. Based on its accumulated data and experience, the company provides high-quality, precise data and plays an important role in the successful execution of clients’ clinical trials through project management that meets stringent global regulatory standards.
In addition, SML Meditree provides integrated services covering the entire clinical trial process, supporting global sponsors in the safe and rapid management of clinical samples through its dedicated biologistics organization, as well as the affiliates and collaborative network of its parent company, Samkwang Biotree Group.
SML Meditree’s success in global business has been driven by the extensive global business development experience of CEO Dong-soo Lee and the collaboration of its dedicated team. Under its vision of making 2025 the first year in which SML Meditree establishes itself as Korea’s leading global clinical trial sample analysis institution (GCLP), the Business Planning Team, which leads the company’s global business, continues to generate results by focusing on strengthening collaboration with overseas sponsors, developing new markets, and providing locally tailored services.
Beyond Asia, SML Meditree also plans to expand its presence in the North American and European markets. The company is strengthening relationships with major global sponsors while continuing to invest in research and development and expand its networks to provide localized solutions. These strategies are expected to help SML Meditree establish itself as a trusted partner in clinical trial sample analysis within the global healthcare market.